SARS-CoV-2 Infection and Lung Regeneration

Area of Science:

• Pulmonary Medicine
• Immunopathology
• Regenerative Medicine

Background:

• The lung is the primary site of SARS-CoV-2-induced immunopathology, with the virus entering host cells via ACE2.
• Lung stem/progenitor cells express ACE2, posing a risk of impaired lung regeneration post-infection.
• Clinical treatments like mechanical ventilation may also impact lung repair mechanisms.

Purpose of the Study:

• To review how SARS-CoV-2 disrupts lung homeostasis and repair programs.
• To summarize current targeted and supportive therapies for COVID-19.
• To discuss the potential of cell therapy for preventing post-COVID-19 sequelae.

Main Methods:

• Literature review of SARS-CoV-2 effects on lung regeneration.
• Analysis of clinical treatments and their impact on lung repair.
• Evaluation of cell therapy strategies for COVID-19 recovery.

Main Results:

• SARS-CoV-2 infection disrupts lung homeostasis and regeneration pathways.
• Existing treatments for COVID-19 have varying effects on lung repair.
• Cell therapies, including mesenchymal stem cells, show potential but require further investigation.

Conclusions:

• Targeting lung regeneration is essential for restoring homeostasis in COVID-19 patients.
• Cell therapy offers a promising avenue for preventing post-acute sequelae of COVID-19.
• A multifaceted approach combining symptomatic treatment and regenerative strategies is needed for optimal COVID-19 patient outcomes.